Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SUPRIYA

SUPRIYA

HealthcarePharmaceuticals & Biotechnology₹4948 cr market cap
₹625.00 ▲ +1.66% today As of 19 Nov 2026
52-week low ₹553.3552-week high ₹1052.50

-41.6% from the 52-week high · +11.1% above the low

Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Antihistamine, Anti-Allergic, Vitamins, Anesthetics, Ant-Malarial and Anti-Asthmatics. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection. Its manufacturing facilities include delineated areas for quality check; manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant.

The short version. Promoter holding was 68.3% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

SUPRIYA trades 41.6% below its 52-week high and 11.1% above its 52-week low.

Change over period: —

1M-29.6%
3M-22.0%
6M-15.2%
1Y-23.4%

4 · The owners

Who holds it, and are they adding?

Promoter holding68.3%

Unchanged over 8 quarters.

Foreign institutions6.44%

Down 0.08 pts over 8 quarters.

Domestic institutions5.47%

Up 0.55 pts over 8 quarters.

Mutual fund schemes20

+10 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter68.368.368.368.368.368.368.368.30.0
FII6.527.196.785.465.25.166.196.44-0.08
DII4.924.264.865.225.015.75.35.47+0.55
Public20.2620.2620.0621.0221.520.8420.2119.79-0.47

Mutual fund holdings · Oct 2026

20 schemes hold this stock

10 the month before.

  • the Quantum Small Cap Fund3.75% of NAV
  • ITI ELSS Tax Saver Fund1.87% of NAV
  • ITI Large & Mid Cap Fund1.49% of NAV
  • ITI Pharma and Healthcare Fund0.89% of NAV
  • the Quantum Flexi Cap Fund0.83% of NAV
  • WhiteOak Capital Pharma and Healthcare Fund0.59% of NAV
  • Abakkus Flexi Cap Fund0.56% of NAV
  • Motilal Oswal Nifty Microcap 250 Index Fund0.27% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SUPRIYA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SUPRIYA

What is the SUPRIYA share price?

SUPRIYA (SUPRIYA) last closed at ₹625.00, up 1.66% on the day. Its 52-week range is ₹553.35 to ₹1,052.50.

What is the market cap of SUPRIYA?

SUPRIYA has a market capitalisation of about ₹4,948 crore. Its price-to-earnings ratio is 27.8.

How are SUPRIYA's latest results?

Promoter holding was 68.3% in Sep 2026, up 0.00 points over 8 quarters.

Who owns SUPRIYA?

As of Sep 2026, shareholding was: Promoter 68.3%, FII 6.44%, DII 5.47%, Public 19.79%.

How many mutual funds hold SUPRIYA?

20 mutual fund schemes held SUPRIYA in October 2026. That compares with 10 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 04 Sep 2025 · Final Dividend - Rs. 1
  • 20 Sep 2024 · Final Dividend - Rs. 0.8
  • 15 Sep 2023 · Final Dividend - Rs. 0.6
  • 01 Sep 2022 · Final Dividend - Rs. 0.6

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.